Navigation Links
Study identifies which men are likely to have persistent prostate cancer
Date:2/14/2008

A new Fox Chase Cancer Center study suggests a biopsy reveals more important information about a mans prostate cancer than previously understood. Doctors hope the new findings will help them tailor radiation treatment.

Radiotherapy offers the chance of a cure for most patients, explained Mark K. Buyyounouski, M.D., M.S., attending physician in the radiation oncology department at Fox Chase Cancer Center. For some, however, an elevated PSA level after treatment indicates the cancer is still around or has come back. Our new study shows how we can use biopsy information prior to treatment to help us predict which patients are most likely to still have disease after treatment. With this knowledge, we can better tailor treatment.

In the study presented by Buyyounouski today at the 2008 Genitourinary Cancers Symposium in San Francisco, researchers compared prostate biopsies taken before treatment with those taken again two years after treatment. All the study volunteers had cancers that were classified as intermediate or high risk.

Larger tumors are believed to be more likely to persist after treatment, but what defines a larger tumor has been controversial, said Buyyounouski. What we found was that a high percentage of cancer observed in the biopsy taken before treatment correlated with a higher probability of a positive biopsy after treatment. This information is important because locally persistent prostate cancer may result in laterspread of the disease and possibly death.

Buyyounouski explained that other researchers have explored the use of biopsy information to identify higher risk of recurrence for men with prostate cancer. Using a percentage of positive biopsy cores has been advocated by some, but these types of studies compared the cores to PSA level after treatment and not post-treatment biopsies.

This study is important because the percentage of cancer seen in the biopsy before treatment is directly correlated with cancer seen in the biopsy in the same location two years after treatment, explained Buyyounouski.

We believe this study will help raise awareness about which patients may be at greatest risk of having persistent prostate cancer and help us improve future treatment.

Buyyounouski said current sophisticated radiation technologies such as IMRT could allow physicians to tailor treatment for these patients.

Our next step in this area of research is to see if we can prevent recurrence by delivering more radiation to the area of the prostate with the greatest amount of cancer.


'/>"/>

Contact: Karen Mallet
karen.mallet@fccc.edu
414-312-7085
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Miami ... attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant ... will present its annual Global Symposium at the Fontainebleau Hotel located in Miami ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke ... its ANCD BRAIN device as the product advances towards regulatory and clinical phases. ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura ... the achievement of Cisco Select certification and SMB specialization. Altura is now ... , In earning the Select Certification, Altura fulfilled the training and exam ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... consumers can save an average of 70% when buying medication online from Canadian ... are available when purchasing from other countries. The report (chart below) compares U.S. ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article in ... teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their primitive ... been used to remove decayed dental matter, and that teeth were then filled with ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
(Date:4/18/2017)... , April 18, 2017  Spero Therapeutics, LLC, a ... treatment of bacterial infections, will present preclinical data supporting ... of multidrug resistant (MDR) Gram-negative infections at the 27th ... April 22-25, 2017 in Vienna, Austria ... ...
Breaking Medicine Technology: